# Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study

> **NCT07351708** · — · COMPLETED · sponsor: **Cai Zerong** · enrollment: 2315 (actual)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07351708
- **Lead sponsor:** Cai Zerong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-06
- **Primary completion:** 2022-12-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 2315 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07351708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07351708, "Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07351708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*